Data Requirements for Old Products/Generics, Bioequivalence

Slides:



Advertisements
Similar presentations
Prequalification of HIV/AIDS Drugs - UN joint activity lPartners* –UNAIDS –UNICEF –UNFPA –WHO –With the support of World Bank lWHO –Manages, provides technical.
Advertisements

Session 6 : Need for good governance Importance of veterinary legislation and its appropriate implementation Jean-Luc ANGOT, CVO, France 14 March 2013.
Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
The Paediatric Regulation
WHO Training Course on Prequalification Introduction Efficacy and Safety Issues Hans Kemmler Consultant to WHO Accra, 5.Nov
Biopharmaceutical Regulatory Requirements 1. Marketing Authorization for Chemical Entities MoH Federal Commission for the Protection against Health Risks.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum 21 CFR Part 11 Considerations November 14, 2002.
FDA Nasal BA/BE Guidance Overview
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
REGISTRATION OF MEDICINES & PROGRESS WITH RESTRUCTURING THE MCC 1.
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
The South African perspective
Bioequivalence and Bioavailability Working Group.
SFDA-2007 الهيئة العامة للغذاء والدواء Bioequivalence Studies of Generic Pharmaceutical Products Workshop-Day II Introduction and workshop Objectives By:
Authorisation of medicinal products: selected challenges Rocío Salvador Roldán Pharmaceuticals Unit/DG SANCO This presentation only reflects the views.
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
TECHNICAL REQUIREMENTS FOR MINOR APPLICATIONS E MOKANTLA 3 SEPTEMBER 2013.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
TANZANIA AUGUST TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININS.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
TM/WSP 5-9 Nov Group C1- Regulatory framework - Nuclear safety - Radiation protection - Security and physical protection QUESTIONS / DIFFICULTIES.
An agency of the European Union Presented by: Kornelia Grein Role of VICH and VICH guidelines in marketing authorizations 2 nd VICH Outreach Forum meeting,
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
Application of VICH GLs – extract from group discussion General: VICH GLs do not prescribe the data package to be submitted for registration, they merely.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
VICH General Principles and current update of VICH Outreach Forum activity 1.
Introduction to the VICH Outreach Forum Steven D. Vaughn, DVM VICH Workshop Dar Es Salaam, Tanzania – June 24, 2015.
GLP/GCP: Requirement and implementation (Japan) Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan 1 5 th VICH Outreach.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1.
An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.
Introduce GLP/GCP into China Shixin XU, PhD, Prof. China IVDC.
Regulation of Generic Animal Drugs in the United States
Session 5: 3Rs statement VICH5 Conference, October 2015, Tokyo 1.
Regulatory Approval Process for Veterinary Drugs – A Global Perspective M. R. Srinivasan and P. Sriram Laboratory Animal Medicine, Centre for Animal Health.
Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.
Session 9: The Vision for the Future 1 Dr. Yuko Endo JMAFF.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
How to comment VICH guidelines Shixin XU, PhD, Prof. China IVDC.
VICH Task Force for Efficacy Studies for Combination Products Progress Report (Final) VICH members JMAFF (chair)K. Noda JVPAE. Oishi IFAH-EUM. Bobey EUK.
How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.
Waiving TABST for vaccines Argentina: Not an allowed procedure today Require batch safety tests in laboratory animals, repeated by authorities Currently.
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
1 1 Topics “out of the scope of VICH” Brigitte Boenisch IFAH-Europe 2 nd VICH Outreach Forum Meeting Washington, 19 th /20 th February 2012 – how and by.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
The Law of the KR «On making amendments and changes to certain legislative acts of the KR» 4 th MeTA Forum in the Kyrgyz Republic Bishkek, December 8,
Update of Results of the Survey on training Priorities
Hervé Marion, DVM VICH Secretariat
VICH General Principles and
Requirements for GLP and GCP in the EU
Introduction of Biopharmaceutics & Pharmacokinetics
Data Managers’ Forum What’s in it for us?
Waiving Target Animal Batch Safety Testing for vaccines
The expectations from VICH Outreach Forum members
The Benefits of VICH to Emerging Countries
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Hervé Marion, DVM VICH Secretariat
NIGERIAN REGISTRATION SYSTEMS OF VETERINARY MEDICINAL PRODUCTS :
Presentation transcript:

Data Requirements for Old Products/Generics, Bioequivalence Data Requirements for Old Products/Generics, Bioequivalence. A Perspective from Argentina 6th VICH Outreach Forum MV Carlos FRANCIA CAPROVE – Cámara Argentina de Productos Veterinarios

Introduction How is a product registered in almost all CAMEVET? The veterinary medicines register system is based on the «new product» concept. Every product, innovative or not, are under the same kind of requirements. To register a “new product”, the owner has to submit a complete application form.

Introduction

Application form The application form is a detailed list of requirements that must be fulfilled. It has four parts Administrative data Quality Efficacy Safety

Innovative vs. Old products Innovative products New API New API combination New formulation with different PK “Old products” Old and well known API (or API combination) Well known formulations

All products Administrative data includes (imported products) FSC Establishment license GMP certificate Quality data must be referred to the proposed product.

Old Products Requirements Efficacy and Safety The information needed can be obtained from technical published works If the product is included in national erradication programs (like mange or bovine ticks), local efficacy and safety tests could be mandatory. Some of these tests are performed by the regulatory authorities

Bioequivalence Proposed uses Under discussion Significant changes in formulation (excipients or process) that could affect bioavailability New administration route for a registered product Under discussion Avoid efficacy or safety trials in products that are pharmaceutical equivalents

Bioequivalence Residue trials? If the bioequivalence study covers all the time required for depletion (withdrawal), bioequivalence could be a useful tool to avoid unnecessary trials that require animal’s death.

Thanks a lot!